Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution

27 Aug 2012

As Sanofi/Genzyme plans to take leukemia drug Campath out of the commercial market in the U.S. and Europe so it will not undercut sales of the same compound in a different indication, patient advocates are confident that a patient-access system will continue providing the drug to those who need it.

The key to Genzyme Corp.’s move to withdraw its leukemia drug Campath (alemtuzumab) to pave the way for a higher-priced introduction of the antibody therapy in the multiple sclerosis marketseems to be in working with the cancer community and establishing generous patient support.

Genzyme, the rare disease unit of Sanofi, is in the process of removing Campath from commercial availability in about...